Simple Summary Patients with myeloid malignancies (blood cancers such as leukemia and
myelodysplastic syndromes) that have returned or worsened despite chemotherapy or a …

Myelodysplastic syndromes/neoplasms (MDS) and related diseases are highly
heterogeneous myeloid stem cell cancers that predominantly affect the elderly. The only …

PURPOSE Decision about the optimal timing of a treatment procedure in patients with
hematologic neoplasms is critical, especially for cellular therapies (most including …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Hematopoietic cell transplantation (HCT) has evolved to an essential treatment in younger
and more recently in elderly patients with myelodysplastic syndrome (MDS), the age group …

Myelodysplastic syndrome (MDS) is a very heterogeneous clonal disorder. Patients with
“higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor …

Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with
either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell …

Presentations in the field of clonal myeloid diseases from the 65th American Society of
Hematology conference provided insights into future therapeutic approaches especially for …

Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells, which
is driven by the acquisition of somatic genetic mutations. Within these disorders …

A new clinical and genetics-based decision strategy shows how patients with low-and
moderate-low risk myelodysplastic syndromes (MDS), according to the Molecular Revised …